Bridge Biotherapeutics "Reveals 2 Idiopathic Pulmonary Fibrosis Projects at US IPF Summit"

[Asia Economy Reporter Lee Gwanju] Bridge Biotherapeutics announced on the 4th that it plans to reveal key preclinical data of its idiopathic pulmonary fibrosis (IPF) drug candidates 'BBT-301' and 'BBT-209' for the first time at the '2022 IPF Summit' to be held over three days starting on the 29th in Boston, USA.

BBT-301 is an innovative drug candidate with a mechanism that selectively regulates the potassium channel (Kca 3.1), which has been observed to be highly overexpressed in patients with idiopathic pulmonary fibrosis. Since acquiring the option for this project from Cellion Biomed in March, Bridge Biotherapeutics has conducted various preclinical studies and plans to present related data in poster form at this academic conference. The main contents include ▲ results of pulmonary functional indicators and pathological improvement indicators in pulmonary fibrosis animal models ▲ analysis results of collagen deposition, a major biomarker of idiopathic pulmonary fibrosis.

Additionally, BBT-209, which will be disclosed, is a 'G protein-coupled receptor 19 (GPCR19)' activating drug introduced from Shaperon in April. It has a mechanism that suppresses fibrotic diseases by activating GPCR19, a receptor that regulates the occurrence of inflammation. At this conference, data comparing pathological improvement indicators in idiopathic pulmonary fibrosis animal models related to BBT-209, as well as expression analysis results of α-smooth muscle actin, a biomarker measuring activated fibroblasts in idiopathic pulmonary fibrosis, will be disclosed based on comparative experiments with competing drugs.

Lee Jung-kyu, CEO of Bridge Biotherapeutics, said, "Interest in our new pipeline is increasing, so we decided to announce preclinical data through this IPF Summit," adding, "We will accelerate the advancement of our fibrosis disease pipeline, which we have designated as a strategic disease area, and strive to provide new treatment options for idiopathic pulmonary fibrosis, where unmet medical needs remain high."